Accueil   Diary - News   All news NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors

NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors

NETRIS Pharma, a pioneer in the development of dependence receptor targeted cancer medicines, announced today the start of enrollment of patients with advanced/metastatic solid tumors in its Phase I clinical study of NP137, a humanized monoclonal antibody targeting Netrin-1 (NCT02977195).

 

The study represents the first time a drug candidate targeting dependence receptors has been evaluated in humans.

 

Dependence receptors are tumor suppressors that trigger cell death unless engaged by a ligand, in this case Netrin-1. Blocking Netrin-1 could re-introduce the natural tumor cell death pathway.

 

 

 

 

 

Read the press release